The ICER Impact.

New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $300 million

Read More

Engaged with over 300 patient groups and patient reps

In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model

Read More

Current

Policy Papers.

Easy access to our ongoing policy papers

Unsupported Price Increases

Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.

Read More

Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19

This white paper provides a brief overview of approaches to manage the pricing of novel vaccines and treatments in times of public health emergencies.

Read More

Cornerstones of ‘Fair’ Drug Coverage

Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, this white paper provides recommendations for appropriate design and implementation of policies that determine patient access to prescription drugs.

Read More

Latest

Developments.


Group of Patients

Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.

Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.

Cost-Effectiveness, the evLYG,

the QALY, and Fair Drug Pricing.

Learn More.